HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Fluorouracil irinotecan sucrosofate Leucovorin Oxaliplatin S 1 (combination) Tegafur